SVP Rare Disease Development
Pediatrician with real-world expertise rare diseases, sphingolipid biology, inflammation and pediatric rheumatology. 13 years clinical and translational research experience, with 8 years in rare disease pharma therapeutic lifecycle development.
Company, Program, and Project level leadership and accountability in international biotech startup setting including build-out, operations, due diligence and program development. Strategic planning and execution in clinical and translational research, lifecycle development, medical, scientific and patient affairs. Experience and understanding of conduct of clinical studies and access to therapies across geographies, cultures and in clinical centers with varying levels of experience and resource availability.
Architect of rhAC clinical development program from its inception. Responsible for clinical and translational development, medical and patient affairs, as well as medical and scientific discussions with FDA and EMA.
Focus on delivering benefit to patients and other stakeholders efficiently and effectively.